Autologous CD34+ Cell Therapy for Refractory Angina: 2 year Outcomes from the ACT34-CMI Study.

Autologous CD34<sup>+</sup> Cell Therapy for Refractory Angina: 2 year Outcomes from the ACT34-CMI Study. Cell Transplant. 2016 May 4; Authors: Henry TD, Schaer GL, Traverse JH, Povisc TJ, Davidson C, Lee JS, Costa MA, Bass T, Mendelsohn F, Fortuin FD, Pepine CJ, Patel AN, Riedel N, Junge C, Hunt A, Kereiakes DJ, White C, Harrington RA, Schatz RA, Losordo DW, Investigators TA Abstract An increasing number of patients have refractory angina despite optimal medical therapy and are without further revascularization options. Pre-clinical studies indicate that human CD34(+) stem cells can stimulate new blood vessel formation in ischemic myocardium, improving perfusion and function. In ACT34-CMI (n=167), patients treated with autologous CD34(+) stem cells had improvements in angina and exercise time at 6 and 12 months compared to placebo; however, the longer-term effects of this treatment are unknown. ACT-34 was a phase II randomized, double-blind, placebo-controlled clinical trial comparing: placebo, low dose (1x10(5) CD34/kg body wt) and high dose (5x10(5) CD34/kg) using intramyocardial delivery into the ischemic zone following NOGA® mapping. To obtain longerterm safety and efficacy in these patients, we compiled data of major cardiac events (MACE: death, myocardial infarction, acute coronary syndrome or heart failure hospitalization) up to 24 months as well as angina and quality of life assessments in patients who consented...
Source: Cell Transplantation - Category: Cytology Authors: Tags: Cell Transplant Source Type: research